Dollar General vs Johnson & Johnson
Side-by-side comparison of AI visibility scores, market position, and capabilities
NYSE: DG | $38.7B revenue FY2024; 20,600+ stores — largest US discount retailer by count; within 5 miles of 75% of US population; serves rural and value-focused shoppers
About
Dollar General is the largest discount retailer in the United States by store count, founded in 1939 by J.L. Turner and Cal Turner Sr. in Scottsville, Kentucky, and headquartered in Goodlettsville, Tennessee. The company was built on the premise that every American — regardless of ZIP code — deserves access to affordable everyday essentials, and Dollar General has operationalized that mission by placing stores within five miles of approximately 75% of the US population. Dollar General trades on the NYSE under the ticker DG and operates with a relentless focus on the price-sensitive, value-seeking consumer who relies on discount retail for staples across food, household goods, health and beauty, apparel, and seasonal merchandise.\n\nDollar General operates more than 19,000 stores across 47 states, with a store model deliberately sized at 7,000–10,000 square feet to serve small towns, rural communities, and urban neighborhoods underserved by traditional grocery and mass-merchandise retailers. The company's private label portfolio — including the Good & Smart, Clover Valley, and DG Health brands — drives margin expansion and shopper loyalty. Dollar General has also expanded its fresh produce availability, health services through DG Fresh, and its pOpshelf concept targeting higher-income suburban shoppers with seasonal, home décor, and entertainment merchandise.\n\nDollar General reported revenue exceeding $38 billion, cementing its position as America's #1 discount retailer by store count. Its store expansion strategy — opening approximately 800 new stores per year — targets rural and semi-rural markets where it faces no direct competition from Walmart or Target. This geographic moat, combined with low-cost operations, everyday-low-price positioning, and a loyal core customer base of budget-constrained households, gives Dollar General a durable competitive position in the value retail segment regardless of macroeconomic conditions.
FY2024 Sales: $88.8B (+4.3%) | Net Profit: $14.1B (+5.6%) | EPS: $5.79 | Adjusted EPS: $9.98 | FY2025 Guidance: Operational Sales Growth 2.5-3.5%, Adj EPS $10.75-$10.95 (+8.7% midpoint)
About
Johnson & Johnson is one of the world's largest healthcare companies, founded in 1886 by brothers Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson in New Brunswick, New Jersey, where the company remains headquartered. Established to manufacture ready-to-use surgical dressings at a time when post-operative infection was a leading cause of surgical mortality, J&J was built on the scientific principles of antiseptic surgery advocated by Joseph Lister. The company trades on the NYSE under ticker JNJ and has evolved over 135+ years from a consumer health products manufacturer into a focused MedTech and pharmaceutical enterprise, completing the spinoff of its consumer health segment (Kenvue) in 2023.\n\nJohnson & Johnson now operates through two segments: Innovative Medicine and MedTech. Innovative Medicine encompasses oncology, immunology, neuroscience, infectious disease, and cardiovascular pharmaceutical products — including blockbusters Darzalex, Stelara, Tremfya, and Rybrevant. The MedTech segment includes surgical robotics (Ottava platform in development), electrophysiology (Abiomed, Biosense Webster), orthopedics (DePuy Synthes), and surgery systems, serving hospitals and surgical centers worldwide. Following the Kenvue separation, J&J is a pure-play healthcare technology and pharmaceutical company with significantly higher growth and margin profiles than its historical blended consumer-pharma-medtech structure.\n\nJohnson & Johnson reported FY2024 sales of $88.8 billion, up 4.3% year over year, with net profit of $14.1 billion, up 5.6%. The company's Innovative Medicine segment continues to grow driven by oncology and immunology portfolio strength, while MedTech benefits from procedure volume recovery and robotic surgery adoption. J&J's scale, R&D pipeline depth, and global commercial infrastructure — spanning more than 60 countries — position it as one of the two or three most consequential healthcare enterprises globally, with a patent portfolio, clinical trial network, and regulatory expertise that are nearly impossible to replicate.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Integrations
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.